Identification
- Summary
Sulfur hexafluoride is a medication used in ultrasound to enhance viewing of blood vessels and the urinary tract.
- Brand Names
- Lumason, Sonovue
- Generic Name
- Sulfur hexafluoride
- DrugBank Accession Number
- DB11104
- Background
Sulfur hexafluoride is an ultrasound contrast agent indicated for use •in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms •in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Sulfur hexafluoride (DB11104)
- Weight
- Average: 146.05
Monoisotopic: 145.962490152 - Chemical Formula
- F6S
- Synonyms
- hexafluoridosulfur
- Sulfur fluoride
- Sulfur hexafluoride
- sulfur(6+) fluoride
- sulfur(VI) fluoride
- Sulphur hexafluoride
Pharmacology
- Indication
Echocardiography: Sulfur hexafluoride is indicated for use in adult patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricularendocardial border. Ultrasonography of the Liver: Sulfur hexafluoride is indicated for use with ultrasound of the liver in adult and pediatric patients to characterize focal liver lesions.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Sulfur hexafluoride provides useful echocardiographic signal intensity for two minutes after the injection. Sulfur hexafluoride microspheres are destroyed and contrast enhancement decreases as the mechanical index increases (values of 0.8 or less are recommended). For ultrasonography of the liver, Sulfur hexafluoride provides dynamic patterns of differential signal intensity enhancement between focal liver lesions and liver parenchyma during the arterial, portal venous, and late phase of signal intensity enhancement of the microvasculature.
- Mechanism of action
Within the blood, the acoustic impedance of Lumason microspheres is lower than that of the surrounding non-aqueous tissue. Therefore, an ultrasound beam is reflected from the interface between the microspheres and the surrounding tissue. The reflected ultrasound signal provides a visual image that shows a contrast between the blood and the surrounding tissues.
- Absorption
The pharmacokinetic of the SF6 gas component of Lumason was evaluated in 12 healthy adult subjects (7 men and 5 women). After intravenous bolus injections of 0.03 mL/kg and 0.3 mL/kg of Lumason, corresponding to approximately 1 and 10 times the recommended doses, concentrations of SF6 in blood peaked within 1 to 2 minutes for both doses.
- Volume of distribution
In a study of healthy subjects, the mean values for the apparent steady-state volume of distribution of SF6 were 341 L and 710 L for Lumason doses of 0.03 mL/kg and 0.3 mL/kg, respectively. Preferential distribution to the lung is likely responsible for these values.
- Protein binding
Not Available
- Metabolism
SF6 undergoes little or no biotransformation; 88% of an administered dose is recovered unchanged in expired air.
- Route of elimination
The SF6 component of Lumason is eliminated via the lungs.
- Half-life
The terminal half-life of SF6 in blood was approximately 10 minutes for the 0.3 mL/kg dose. (At the 0.03 mL/kg dose, terminal half-life could not be estimated.)
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Sonovue Powder, for suspension 8 mcL / mL Intravenous; Intravesical Bracco Imaging S.P.A. 2016-09-22 Not applicable Canada 
Sonovue Injection, powder, for solution 8 μl/ml Intravenous Bracco International B.V. 2016-09-08 Not applicable EU 
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image LumaSon Sulfur hexafluoride (60.7 mg/1mg) + 1,2-Distearoyllecithin (.19 mg/1mg) + Sodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (.19 mg/1mg) Kit Intravenous; Intravesical Bracco Suisse SA 2015-01-15 Not applicable US 
Lumason Sulfur hexafluoride (60.7 mg/1mg) + 1,2-Distearoyllecithin (.19 mg/1mg) + Sodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (.19 mg/1mg) Injection, powder, lyophilized, for suspension Intravenous; Intravesical Bracco Diagnostics Inc 2021-04-01 Not applicable US LumaSon Sulfur hexafluoride (60.7 mg/1mg) + 1,2-Distearoyllecithin (.19 mg/1mg) + Sodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (.19 mg/1mg) Injection, powder, lyophilized, for suspension; Kit Intravenous; Intravesical Bracco Diagnostics Inc 2020-01-15 Not applicable US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as other non-metal halides. These are inorganic compounds containing 'other non-metals' and halogen.
- Kingdom
- Inorganic compounds
- Super Class
- Homogeneous non-metal compounds
- Class
- Other non-metal halides
- Sub Class
- Not Available
- Direct Parent
- Other non-metal halides
- Alternative Parents
- Not Available
- Substituents
- Other non-metal halide
- Molecular Framework
- Not Available
- External Descriptors
- sulfur coordination entity (CHEBI:30496)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- WS7LR3I1D6
- CAS number
- 2551-62-4
- InChI Key
- SFZCNBIFKDRMGX-UHFFFAOYSA-N
- InChI
- InChI=1S/F6S/c1-7(2,3,4,5)6
- IUPAC Name
- hexafluoro-λ⁶-sulfane
- SMILES
- FS(F)(F)(F)(F)F
References
- General References
- FDA label [Link]
- External Links
- KEGG Drug
- D05962
- PubChem Compound
- 17358
- PubChem Substance
- 347827897
- ChemSpider
- 16425
- 1599276
- ChEBI
- 30496
- ChEMBL
- CHEMBL1796998
- ZINC
- ZINC000245224194
- Wikipedia
- Sulfur_hexafluoride
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Active Not Recruiting Diagnostic Abdominal Injuries / Falls, Accidental / Motor Vehicle Injury / Physical Abuse 1 4 Completed Diagnostic Abdominal Trauma 1 4 Completed Diagnostic Hepatic Disease 1 4 Completed Other Hepatocellular Carcinoma 1 4 Recruiting Diagnostic Renal Malignant Tumor 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, lyophilized, for suspension Intravenous; Intravesical Injection, powder, lyophilized, for suspension; kit Intravenous; Intravesical Kit Intravenous; Intravesical Injection, powder, for solution Intravenous 8 μl/ml Powder Intravenous; Parenteral 8 MCG/ML Powder, for suspension Intravenous; Intravesical 8 mcL / mL Injection, powder, for solution Intravenous 8 microlitres/ml - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US5686060 No 1997-11-11 2017-11-11 US US10232061 No 2019-03-19 2038-07-06 US US10335502 No 2019-07-02 2038-07-06 US US11723869 No 2019-05-15 2039-05-15 US
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP 2.28 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 0 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 0 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 18.44 m3·mol-1 Chemaxon Polarizability 7.11 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 120.86147 predictedDeepCCS 1.0 (2019) [M+H]+ 122.782585 predictedDeepCCS 1.0 (2019) [M+Na]+ 131.15828 predictedDeepCCS 1.0 (2019)
Drug created at December 03, 2015 16:51 / Updated at June 03, 2022 07:24